Biomarkers in Leishmaniasis: From Basic Research to Clinical Application by Esteves, Sofia et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Biomarkers in Leishmaniasis: From Basic Research to
Clinical Application
Sofia Esteves, Inês Costa, Célia Amorim,
Nuno Santarem and Anabela Cordeiro-da-Silva
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.75315
Abstract
Leishmania is an intracellular protozoan parasite and the etiological agent of a vector-borne
disease known as leishmaniasis. This neglected tropical disease exhibits high morbidity
and mortality putting at risk people from multiple countries worldwide. It is endemic in
97 countries and 700,000–1 million new cases are estimated to occur each year. Leishman-
iasis management is very challenging, the symptoms are non-pathognomonic (in both
human and canine populations) and the treatments are associated with significant toxicity.
Therefore, the need for detection in symptomatic and asymptomatic hosts is important to
tackle the dissemination of infection, increasing the need for highly specific biomarkers. In
this complex the available disease biomarkers will be addressed in a retrospective manner,
focusing on their development from laboratory to their direct use in clinical settings.
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1. Introduction
1.1. Leishmaniasis as a neglected tropical disease
Neglected tropical diseases are a diverse group of diseases that prevail in tropical and sub-
tropical countries. The geographical distribution of these diseases associated with lack of
sanitation, close contact with domestic animals, livestock and infectious vectors contributes to
disease dissemination, affecting more than 1 billion people and costs billions each year in
developing economies.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Leishmaniasis is a devastating and significantly under-recognized vector-borne disease that
causes serious global health burden. After malaria, it is the second parasitic disease with the
highest mortality rate [1]. It mainly affects populations in Africa, Asia and Latin America, and
is associated with malnutrition, population displacement, poor housing, weak immune system
and lack of resources [1].
Although this disease was initially limited to the tropics and subtropics, several factors lead to
the spread of leishmaniasis to new locations [2]. Perturbations of the natural vector ecosystem
caused by urbanization, deforestation, global warming and natural disasters have a serious
impact in disease dissemination. Increased people and animal migration, traveling and mili-
tary operations contribute to disease spreading. Organ transplantation, lack of Leishmania scr-
eening in the blood bank or immune suppressive therapies can also contribute to disease
perpetuation [2, 3].
This disease can be presented in several ways, the most common ones being: Cutaneous Leish-
maniasis (CL), Mucocutaneous Leishmaniasis (MCL) and Visceral Leishmaniasis (VL), also
known as kala-azar. Depending on the specific clinic-pathological form of the disease, symptoms
range from cutaneous and mucosal tissue lesions to vital visceral organ damage [4, 5].
1.2. Epidemiology
Out of 200 countries and territories reporting to WHO, 97 are endemic for leishmaniasis
(Figure 1). This includes 65 countries endemic for both VL and CL, 10 countries endemic only
for VL and 22 endemic only for CL (Figure 1) [1].
Ninety percent of global VL cases were reported from seven countries: Brazil, Ethiopia, India,
Kenya, Somalia, South Sudan and Sudan. About 95% of CL cases occur in the Americas, the
Figure 1. World map: Human leishmaniasis distribution. VL, Visceral Leishmaniasis; CL, Cutaneous Leishmaniasis;
MCL, Mucocutaneous Leishmaniasis. Status of endemicity of the different forms of leishmaniasis in 2016, according to
the World Health Organization.
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Mediterranean basin, Middle East and Central Asia. An estimated 0.6–1 million new cases occur
worldwide annually. Over 90% of MCL cases occur in Bolivia, Brazil, Ethiopia and Peru [1].
1.3. Clinical forms of the disease
CL is the most common form of leishmaniasis affecting humans. It is a skin infection that
develops as a nodule in the site of inoculation, consequence of macrophage infection in the
dermis. This may progress to a dermal granuloma, an ulcer that heals spontaneously or several
inflamed ulcers, on the exposed parts of the body, such as the face, arms and legs [1, 5, 6].
These lesions can take months or years to heal and may leave behind atrophic scars with a
hyperpigmented halo [2]. The incubation period ranges from 1 week to several months [1].
MCL is less common than CL. Unlike CL, which is confined to small areas of the skin, MCL
aggressively spreads to the oral and nasal mucosa and is characterized by progressive ulcers
and lesions of the face leading to significant disfiguration. The lesions can lead to partial or
total destruction of the mucous membranes of the nose, mouth, throat cavities and surround-
ing tissues [1]. These progressively destructive ulcers, unlike CL, are not self-healing and can
appear months or years after the first episode of CL. The dynamic and evolution of MCL is not
completely understood [4, 7]. In endemic areas, it has been noted that in 1–10% of patients, the
CL form evolves into MCL 5 years after healing [3].
VL, also known as kala-azar, is the most severe form of leishmaniasis and is fatal if left
untreated in over 95% of cases [1, 8]. An incubation period (from 1 month to 2 years) is
followed by clinical manifestations such as fever, splenomegaly, hepatomegaly, weight loss,
progressive anemia and pancytopenia. These systemic infection symptoms are associated to
the dissemination of parasites throughout the blood and reticuloendothelial system and lead
to enlarged lymph nodes, spleen and liver [5].
Post-kala-azar Dermal Leishmaniasis (PKDL) is a complication of VL in areas where
Leishmania donovani (L. donovani) is endemic. It is characterized by a hypopigmented mac-
ular, maculopapular, and nodular rash in a patient suffering a sequel of VL where the skin
is the main focus of the infection. It usually appears 6 months to 1 or more years after
apparent cure of the disease but may occur earlier or even simultaneously with visceral
leishmaniasis [1, 9]. PKDL is confined to two geographically distinct zones, South Asia
(India, Nepal, and Bangladesh) and East Africa (Sudan). In the South Asian variant,
polymorphic lesions (macules/patches with papulonodules) are frequent, while the Suda-
nese variant has papular or nodular lesions. Lesions, especially the papulonodules, are
parasite-rich, driving speculation that PKDL plays an important role in anthroponotic
transmission of VL [10].
1.4. The vector
Leishmania protozoan parasites are transmitted by the bite of a very small (2–3 mm long) insect
vector, known as the phlebotomine sandfly. Solely the female sandfly transmits the parasites,
and only 30 from the 500 species of phlebotomine transmit this disease [1]. Female sandflies
become infected with Leishmania parasites upon a blood meal from an infected person or
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animal which they need for egg development. Over a period between 4 and 25 days, the
parasites develop in the sandfly. This development period can be extended at low tempera-
tures or shortened at high temperatures [3]. The transmission cycle is completed when the
infectious female sandfly feeds and inoculates a host with the parasite [1].
1.5. Life cycle
The parasite life cycle requires the transmission of infectious protozoan between sandflies and
a mammalian host. Leishmania parasites present two distinct forms: promastigotes and
amastigotes. Promastigotes are the flagellated, motile forms of the parasites that develop and
morphologically differentiate in the sandfly midgut to an infectious metacyclic form that is
transmitted to the mammalian host when the sandfly takes a blood meal. These metacyclic
promastigotes are phagocytosed by mono and polymorphonuclear cells and transformed into
the ovoid shape with short flagellum known as amastigote. Upon differentiation, they repli-
cate within the host cells. The replication may lead to the rupture of these cells, allowing
infection of other phagocytes. The life cycle becomes complete when the sandfly takes another
blood meal with amastigotes [11, 12].
Different Leishmania species are capable of causing disease and, depending on the species, the
mammalian host presents different symptomatology. Although being divided by clinical
symptoms, these species can also be divided by their geographical distribution in two main
groups: Old World (the Eastern Hemisphere) species and New World species (caused by
Leishmania species found in Central and South America) [2] (Table 1).
Location Complex Species Clinical forms of the disease
Old World Leishmania donovani L. donovani CL, VL, PKDL, MCL (rare)
L. infantum CL, VL (children), PKDL, MCL (rare)
Leishmania tropica L. tropica CL, MCL (rare), VL (rare)
L. major CL, MCL (rare)
L. aethiopica CL, DCL
New World Leishmania mexicana L. mexicana CL, DCL (rare)
L. amazonensis CL, DCL, MCL, VL (rare), PKLD (rare)
L. venezuelensis CL, DCL (rare)
Leishmania (Viannia) braziliensis L. braziliensis CL, MCL, VL
L. panamensis CL, MCL
L. guyanensis CL, MCL
L. peruviana CL
Leishmania donovani L. infantum CL, VL (children), PKDL, MCL (rare)
VL, Visceral Leishmaniasis; CL, Cutaneous Leishmaniasis; MCL, Mucocutaneous Leishmaniasis; PKDL, Post-Kala-azar
Dermal Leishmaniasis; DCL, Diffused Cutaneous Leishmaniasis. Adapted from Kevric et al. [2].
Table 1. Geodistribution of the organisms prevalent and disease patterns.
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VL form, the most severe form of leishmaniasis, is caused by L. donovani (East Africa and the
Indian subcontinent) and L. infantum (Europe, North Africa, Latin America). While L. donovani
infects all age groups, L. infantum infects mostly children and immunosuppressed individuals.
However, due to increasing prevalence of Human Immunodeficiency Virus (HIV) infection in
the Mediterranean basin, HIV-VL coinfection in the adult population is reported frequently [13].
1.6. Transmission pattern
There are two types of disease transmission: zoonotic, where the disease is transmitted from
animal to vector and then to human; and anthroponotic, transmitted from human to vector to
human. Transmission also varies according to geographical regions, where L. donovani is respon-
sible for anthroponotic transmission and L. infantum for zoonotic transmission. Traditionally,
anthroponotic transmission occurs in the Indian subcontinent and East Africa, and zoonotic
transmission is mostly restricted to the Mediterranean basin and South America regions.
L. donovani is found only in the Old World (except for transmission in patients that have
traveled), where it is notoriously associated with VL of the rural poor areas in the northeast of
the Indian subcontinent and with VL in East Africa [8, 14]. L. infantum is mostly associated to
the zoonotic disease with the dog as a natural reservoir.
Domestic animals play a role as new opportunistic hosts, in vector adaptation to urban
environments [3]. Animals such as the wild canid, marsupials and rodents have been
described as reservoirs of human VL [15]. However, zoonotic VL epidemics have been associ-
ated only in areas where Canine Leishmaniasis (CanL) is endemic (Figure 2), indicating that
dogs are the main reservoir in this type of transmission [16]. Due to the proximity of domestic
dogs and human populations, CanL control is more than a veterinary concern, it is also a
public health issue due to the zoonotic potential of the disease.
1.7. Canine leishmaniasis
CanL is a major concern for the veterinary community, having high mortality and morbidity
rates. Moreover, in endemic areas, domestic dogs are the primary target of infection allowing
perpetuation of the life cycle [17].
Figure 2. World map: Regions with higher canine leishmaniasis incidence – Brazil, Mediterranean basin and China.
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After an incubation period that can range from 3 months to several years, dogs may start
presenting clinical signs. However, some dogs remain asymptomatic and never develop any signs
[17]. Therefore, dogs can present different forms of the disease: symptomatic, oligosymptomatic
and asymptomatic. Dogs that develop few mild symptoms are classified as oligosymptomatic.
Even so, it is relevant to mention that it is not consensual that all forms of the disease enable the
transmission of the parasite. Infected dogs present non-specific cutaneous alterations such as
alopecia, onychogryposis, dermatitis, skin ulceration, anorexia, weight loss and visceral manifes-
tations with splenic, renal and hepatic disorders [18], making an accurate diagnosis impossible.
Given that canine disease usually precedes the appearance of human cases and a clear correla-
tion between canine and human infection rates has been demonstrated, CanL must be consid-
ered as a risk for human health [3].
2. Importance of diagnosis
The available therapies for leishmaniasis are far from optimal due to their toxicity, high costs,
lack of efficacy, lack of access in certain areas, and emerging drug resistance. Treatment efficacy
depends on strains and species and there are currently no effective vaccines available for any
form of human leishmaniasis [2].
Some vaccines exist for veterinary use. Being launched in Portugal in 2011, CaniLeish® was the
first vaccine for CanL in the European Union. In Brazil, LeishTec® vaccine was also registered
but only offers about 40% of protection against infection. LetiFend® has recently been regis-
tered in Europe, but there is limited information available [19]. Despite the efforts, Leishmania
vaccinology still has a lot to improve till an effective and universal vaccine is developed [20].
In the absence of human vaccines and due to the zoonotic character of the disease, accurate
detection of infection in humans and dogs is crucial for the control of leishmaniasis [21].
Several specific challenges associated to Leishmania infection and leishmaniasis must be over-
come. As for any disease, the diagnostic process should be simple, robust, automated, requir-
ing inexpensive reagents and minimal operator intervention without diminishing the fidelity
of the results. Notwithstanding, considering that this disease affects mostly poor people in
countries with undeveloped and underfinanced health systems, the tests should be cheap and
easy to perform in field conditions [22, 23]. Moreover, the detection of asymptomatic infection,
often characterized by reduced parasite loads and low specific serology, is essential. In fact,
clinical and epidemiological management of Leishmania infections can only be fully successful
once a diagnostic test with these characteristics is available [24]. The available tools are ade-
quate for detection of disease, (in conjunction with clinical evaluation) but present limitations
for diagnosis of infection in asymptomatic patients and dogs. Therefore, the information of real
prevalence of infection and overall burden of disease is believed to be underestimated [22].
Coinfection with HIV is common in VL cases and has a disastrous impact since immunocom-
promised individuals have more severe manifestations and atypical symptoms that complicate
treatment [2]. Pregnant women can be considered a risk population, as HIV-infected patients,
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being more susceptible to Leishmania relapse and changes in immune response. Immunosup-
pression by HIV had an enormous impact and highly contributed to the increased number of
leishmaniasis cases [3]. Coinfection of L. donovani and L. infantumwith HIV has been identified
as a meaningful clinical problem, and presents higher mortality rates. Up to 70% of VL cases in
southern Europe are associated with HIV infection. VL is the third most frequent opportunistic
infection in many parts of the world, and the coinfection with HIV is now reported in 35
countries [25].
3. Biomarkers to use in diagnosis
Every methodology has a detection limit associated but the specificity of the diagnosis plat-
form is mostly influenced by the antigen used, relying on it to produce high confidence results.
Several antigens were proposed overtime but the most common one is crude soluble antigen
(CSA) [13, 26]. Although the sensitivity of CSA in Enzyme-Linked Immunosorbent Assay
(ELISA) is high, cross-reactivity with other diseases (trypanosomiasis, toxoplasmosis and
tuberculosis) occurs frequently, leading to false positive results [27, 28]. Therefore specificity
can be low due to cross-reactivity and is not suitable in detecting seropositivity in asymptom-
atic dogs [29–31]. This is transversal to other serological techniques like Direct Agglutination
Test (DAT) or Indirect Fluorescent Antibody Technique (IFAT) which are based on the recog-
nition of the parasite total antigens. The specificity and sensitivity problems associated to
conventional assays (such as IFAT, DAT, and CSA ELISA) may be overcome using recombi-
nant polypeptides containing specific epitopes that are able to induce an immune response in
most dogs and humans with VL. Hence, there has been a focus on expressing and purifying
Leishmania proteins that elicit an immune response in dogs and humans and analyze them and
their potential for serological tests [32–34].
The evolution of molecular technology (immunoproteomics) and sequencing of the Leish-
mania genome in 2005 have been powerful tools for the discovery of recombinant Leishmania
proteins to use in the serodiagnosis of human and canine leishmaniasis [35, 36]. Variability in
the humoral response concerning different parasite antigens observed in infection suggests
that a combination of recombinant proteins can improve the diagnosis efficiency [37]. In fact,
each antigen carries often both specific immune-dominant epitopes and other regions that
are not important for serological recognition [38]. Therefore, an ideal test would contain a
combination of relevant epitopes in a single recombinant antigen, more specific than crude
antigen preparation and more sensitive than single epitope-based ELISA [39]. In fact, chime-
ric multi-epitope proteins are part of the future strategy to look for novel high specific
antigens [40]. Several recombinant proteins with high efficacy have reasonable results for
the diagnosis of human and canine VL, but development of suitable antigens for diagnosis is
still necessary [34].
The most common used antigens belong to different protein families, such as the kinesin-
related proteins, heat shock proteins, acidic ribosomal proteins, nuclear proteins, enzymes
and other antigens which are associated with parasite function [41].




Kinesins are a family of motor proteins in eukaryotic cells, and constitute part of the
microtubule cytoskeleton in Leishmania parasites, important in its growth and differentia-
tion [42–44].
Several Leishmania antigens have been characterized, as the recombinant K39 antigen (rK39), a
39-aminoacid-repetitive B-cell epitope of the kinesin-related protein of L. infantum. The rK39
ELISA has shown to be capable of detecting human and canine VL.
The K9 and K26 are two other hydrophilic antigens of L. infantum, and their recombinant
antigens (rK9 and rK26) have been used to diagnose VL. The rK28 is a recombinant fusion
protein with tandem repeats of K39 kinesin regions and K26, and has been used to detect high
levels of antibody responses in infected patients, using ELISA [13, 37].
The rK39, an antigen used for VL diagnosis, is highly conserved among VL species [15].
Several studies carried out in VL endemic areas have demonstrated that the rK39 ELISA is a
sensitive and a specific method for the serodiagnosis of human VL [34, 45–47]. An important
aspect of the anti-rK39 antibody is that the titer correlates directly with the disease activity,
indicating its potential for use in predicting response to therapy [48]. The rk39 has also been
tested for ELISA and Flow Cytometry (FC) assays showing high sensitivity and specificity in
detecting clinical forms of CanL [49]. rK39 is further addressed in Section 5—Successful
diagnosis approaches—from laboratory to field conditions.
VL patients also have a strong antibody response to K26, which can complement rK39 in a
better and more accurately diagnosis of human VL [50]. Specific and independent antibody
reactivity to each of these antigens (rK9, rK26 and rK39) have been studied and tested in
serodiagnosis of canine VL [31, 51].
Another antigen that has been successfully used in the diagnosis of human VL is rK28. This
recombinant fusion antigen was used for ELISA and has shown sensitivity and specificity
values similar or higher than those obtained for rK39. Therefore, this antigen has been pro-
posed as a new choice, especially regarding regions where rK39 has shown low levels of
sensitivity [52]. In Sudan and in India [53], human serological surveys using rK28 antigen have
shown good performance with high sensitivity and specificity [54]. ELISA with rK28 antigen
was 100% sensitive and specific in serological diagnosis of CanL [54]. The sensitivity of rK28
was slightly higher than rK39, although no significant differences in the detection of positive
dogs were observed, indicating that both antigens may be useful for diagnosing CanL, as
previously observed in VL in human [54, 55].
KE16 is another kinesin gene derived from the C-terminus of the kinesin protein from an
isolate of L. donovani [56] that has been successfully cloned and expressed. It is used in the
rKE16 dipstick test, a one-step rapid immunochromatographic test. Results showed that this
antigen can be used as a highly specific and sensitive tool for VL diagnosis, although, in dogs,
the average of positive cases among asymptomatic dogs was low [34, 56, 57].
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3.2. Heat shock proteins
Heat Shock Proteins (HSPs) are a family of proteins that are produced by cells in response to
stressful conditions. They are highly conserved molecules that play important roles in protein
folding, assembly of protein complexes, and translocation of proteins across cellular compartments.
The L. donovani HSP70 was identified after screening of a cDNA library with serum from a
patient with VL [58]. It is found in prokaryotic and eukaryotic cells and is a highly conserved
protein. HSP70s from other Leishmania species (L. infantum and L. braziliensis [59]) have also
been characterized.
rHSP70 had high sensitivity and specificity values, being superior to CSA in the diagnosis of
CL [60]. The antigenicity of heat shock proteins in general and of HSP70 specifically is not
unexpected, since antibodies against the parasite recombinant HSPs have been found in sera of
patients with different parasitic diseases [61, 62]. Other authors have described rHSP70 as a
preeminent antigen present in Leishmania [63]. Specific antibodies against L. braziliensis rHSP70
or rHSP83 were found in 95% of sera fromML or CL patients and a high recognition of rHSP70
by sera from the same patients has been detailed [59].
L. infantum-rHSP83 is a possible antigen to be used in the serodiagnosis of leishmaniasis, due
to its high specificity and sensitivity and insignificant cross-reactivity with other infectious
diseases [48]. Members of the HSP83/90 family have also been described as immunodominant
antigens during infections caused by L. donovani, L. braziliensis and L. infantum [64].
Another gene, LmSti1, encoding a stress-inducible protein STI1 [65] was strongly recognized in
sera from human patients with CL, VL and post-kala azar CL [48].
3.3. Ribosomal proteins
Ribosomal proteins have been described to induce antibodies in animal and humans infected
with the parasite, making them a favorable candidate to assess its diagnosis potential.
Studies have described some Leishmania ribosomal proteins function as immunoregulatory
molecules [41, 59]. As a matter of fact, the eukaryotic ribosome is composed of four RNA
molecules and more than 70 ribosomal proteins [66]. Furthermore, the acidic ribosomal
proteins (P-proteins) have been detailed as prominent antigens during Leishmania infections
[41, 67].
The large subunit of ribosomes contains various copies of a protein called P protein. P1, P2 and
P0 form a complex notorious for having an essential role in protein synthesis. Three L. infantum
antigens (LiP2a, LiP2b and LiP0), homologous to acidic ribosomal proteins, were identified
after immunoscreening of a cDNA expression library with CanL serum [68]. They are also
recognized by sera from patients with either VL or MCL [41, 69].
The ribosomal proteins LiP2a, LIP2b, LiP0/LcP0 and LeIF, all conserved antigens of Leishmania,
have been shown to be recognized by the immune system of the host [70].
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The L. infantum acidic ribosomal proteins, LiP2a and LiP2b, have disease-specific antigenic
determinants identified by more than 80% of canine VL [70]. Engineered LiP2a and LiP2b
recombinant proteins are shown to be useful as tools to discriminate between VL and Chagas
disease [71]. L. infantum P0 ribosomal protein is also recognized by a high percentage of the
sera from dogs with VL [70].
The acidic ribosomal proteins (P1, P2 and P0) are recognized by antibodies frequently found in
sera from systemic lupus erythematosus (SLE) patients. These autoantibodies recognize an
amino acid sequence located at the C-terminal ends of the three P proteins [72]. Furthermore,
patients with chronic Chagas heart disease produce a strong humoral response against the C-
terminal of Trypanosoma cruzi ribosomal P proteins. Leishmania ribosomal P2a and P2b C-
terminal end of the proteins is also well conserved and these proteins are recognized by sera
from both SLE and Chagas disease patients [69]. The anti-P antibodies produced during the
Leishmania infection do not recognize the conserved C-terminal domain of the P proteins.
Therefore, to avoid cross-reactivity, engineered versions of the recombinant proteins LiP2a
and LiP2b, without the C-terminal ends, have been found to be useful for the diagnosis of
MCL and VL [69].
3.4. Peroxiredoxins
Tryparedoxins belong to a particular class of oxidoreductases related to thioredoxins and
found in trypanosomatids. They bear oxidoreductase activity toward disulfide bridges and
are crucial to the parasite, as they are expressed in all stages of development [73]. These
proteins are believed to be involved in Leishmania detoxification of peroxides.
LiTXN1 protein is present in the cytosol and upregulated in the infectious forms of the
parasite, indicating that it plays an important role during infection. LiTXN1 preferentially
reduces the cytosolic L. infantum peroxiredoxins, LicTXNPx1 and LicTXNPx2 [73].
LicTXNPx antigen is highly immunogenic during both human and canine infections [74].
High antibody titers are found during the Leishmania infection and these decrease after its
resolution [75].
Anti-LicTXNPx antibodies are present in both symptomatic and asymptomatic experimental
canine infections, making this antigen a good candidate marker and a prognostic indicator for
monitoring the response to CanL treatment [75]. An ELISA with both LicTXNPx and rK39
antigens (LAM-ELISA) was performed to improve specificity and sensitivity of this methodol-
ogy and presented promising results. This test associated with DATmay be a valuable tool for
screening CanL [22, 30].
3.5. Cysteine proteinases
This family of proteins is associated to disease progression. Activity of cysteine proteases can
be found in parasite surface or inside the macrophage endoplasmatic reticulum. Domains of
cysteine proteinases (CP), type I (CPB) and type II (CPA), were used to diagnose active and
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recovered cases of VL in both humans and dogs. Leishmania cysteine proteinases had already
been used as vaccines targets and in chemotherapy [76].
A recombinant cysteine proteinase from L. chagasi, rLdccys1, has shown to be a good bio-
marker for the different stages of both human and CanL. ELISA assays showed high sensitivity
and specificity. Moreover, the fact that it is possible to detect clinical and subclinical forms of
the disease in canines indicates that this biomarker is important in the control of CanL in
endemic areas [77, 78].
3.6. Nuclear proteins
Histones are structural proteins involved in the organization and function of DNA within the
eukaryotic nucleus. There are four main classes of histones: H2A, H2B, H3 and H4 which form
the nucleosomal core unit of chromatin. These proteins are among the most conserved proteins
in eukaryotic organisms, maintaining sequence and function in trypanosomatids. Histones are
prominent antigens found in animals during Leishmania infection that trigger a specific
immune response and antibody production [39]. Also, sera from children infected with VL
specifically recognize the L. infantum H2A and H2B histones, with high specificity and sensi-
tivity in ELISA assays.
3.7. A2 proteins
A2 proteins of L. donovani are only present in the amastigote stage, and help visceralization of
parasites in the mammalian host. They are overexpressed in the amastigote stage in L. donovani
as well as L. mexicana species complex, including L. amazonensis, but not in L. tropica or
L. braziliensis species complexes. Anti-A2 antibodies were detected in human and dog sera
suffering from active VL [79, 80]. Also, it was found that rA2 is more sensitive when compared
to the rK39 and rK26 antigens, for serological detection of asymptomatic infection in dogs [34].
3.8. Leishmania homolog of receptors for activated C kinase
Leishmania homolog of receptors for activated C Kinase (LACK) was identified after a search
for parasite antigens recognized by a protective Th1 clone derived from the spleen of BALB/c
mice that had been vaccinated with a soluble extract of L. major promastigotes. It has been
proposed that the LACK protein contains an immunodominant epitope that acts as a target of
early immune responses [41, 81].
3.9. rKLO8
Sudan has the highest number of reported cases in East Africa [82], in particular in eastern and
central regions. Field tests based on rK39 commonly have a high reliability in various countries
[83, 84]; however, the low sensitivity in Sudan limits its use in this region. A novel L. donovani-
derived recombinant immunodominant protein (rKLO8) was tested for detection of VL in
Sudan.
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The results presented with rKLO8 show increased reactivity with patient sera as compared to
rK39 ELISA [85]. The rKLO8 ELISA is more sensitive than the DATand rK39 strip test, and VL
patients from Sudan were tested and have decreased immune responses to rK39, confirming
the low sensitivity of rK39 strip test in Sudan. Malaria is common in VL endemic regions of
Africa and Asia [86] and is known to be a major cause of cross reactivity to rK39 [84]. Sera of
malaria patients were tested and did not give a signal in the rKLO8 ELISA. In conclusion,
rKLO8 is a novel recombinant protein of L. donovani with increased reactivity to VL sera from
Sudan and a valuable candidate to be used in diagnosis in this area [84].
3.10. Secreted proteins
Traditionally the intrinsic intracellular and surface proteins of the parasites were targeted as
primary source of antigens. Recently, secreted proteins are considered an untapped source of
possible antigens and are being exploited using combinations of bioinformatic and
immunoproteomic approaches [87, 88] .
3.11. Lipids
Lipid levels are known to vary in acute and chronic infections. In these infections, there is
typically a decrease of total cholesterol levels and an increase in the concentration of
triglyceride-rich lipoproteins; mainly very low-density lipoproteins. Moreover, apolipoprotein
A1, apolipoprotein B and low-density lipoprotein cholesterol levels decrease. In leishmaniasis,
this lipid concentration difference may have a prognostic and diagnostic role, as lipids play an
important role in the innate and adaptive immune response. Although these have potential as
clinical markers, several factors have to be taken into account when interpreting lipids values,
such as: genetic and environmental factors, malnutrition, reduced food intake during acute
infection, and acute kidney injury and/or acute liver failure (many times associated with this
neglected disease), all which influence lipids parameters. More efforts have to be put in the
study of these molecules as disease markers [89].
4. Diagnosis approaches
Due to its wide range of manifestations, leishmaniasis diagnosis can be difficult [90]. Clinical
manifestations can also be confused with other illnesses, often common in Leishmania endemic
areas, such as malaria, toxoplasmosis and tuberculosis [91]. Age, medical history and host
immune system response are crucial parameters for diagnosis.
Diagnosis of diseased patients and animals can be confirmed with conventional laboratorial
techniques, such as visualization of the parasite in tissues by microscopic examination of a
stained specimen, or in vitro culture of the parasite from biopsies or aspirates from lesions,
lymph nodes, spleen and bone marrow. Other diagnosis methods include molecular detection
of parasitic DNA in tissue samples and serological tests that detect anti-Leishmania antibodies
[6]. Overall, the available techniques can detect active disease. Still, leishmaniasis has intrinsic
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particularities that require not only the detection of symptomatic (diseased) conditions but also
asymptomatic (infected, not diseased). This control is important, especially in the context of
CanL, as the asymptomatic animals act as reservoirs, and as mentioned above, increase the risk
for the human variant of the disease. An already complex scenario rendered more complicated
by the need to distinguish treated, exposed and vaccinated. Therefore, leishmaniasis is a very
particular disease and one of the many examples where ongoing research for a new and
affordable diagnosis approaches is necessary.
4.1. Parasitological diagnosis
The gold standard for diagnosis is the microscopic observation of parasites in tissue samples.
Parasite rich localizations like bone marrow, skin lesions, liver, lymph nodes and spleen are
preferred. Identification of amastigotes by direct examination of aspirates is also possible but
must be done by experts since the results are often dependent on the observer [6]. It can also
originate false negative results due to the low number of parasites in some samples, particu-
larly in asymptomatic cases. Most often, diagnostic is obtained by observation of the Leish-
mania amastigote forms in stained microscopic preparations with Giemsa [8]. The best results
are obtained with parasite rich regions like spleen aspirates. With bone marrow aspirates, the
sensitivity decreases considerably and lymph nodes aspirates have the worst sensitivity ranges
[4]. This method requires trained personnel and involves invasive sampling, a risky procedure
that can lead to fatal hemorrhage, which can only be performed in a place with access to
appropriate medical facilities. Lymph node and bone marrow aspirates are safer; however,
material obtained is less concentrated and therefore less sensitive, elevating the risk of false
negatives [92]. All these methods include invasive sampling, are time-consuming and imprac-
ticable to be performed on a large scale [3].
The culture of infected tissues is another classical diagnostic test, although the major problem
with this technique is that different species of Leishmania can have different growth require-
ments and contaminations are recurrent. The culture is performed through the inoculation of
the triturated tissue in adequate media. Both techniques (microscopic exam and culture) have
an overall sensitivity of around 85% [3]. The best results are obtained with spleen aspirates
(93–98% of sensitivity). When it comes to bone marrow aspirates, the sensitivity comes down
to 60 to 85% and worse results are obtained with lymph nodes aspirates (sensitivity ranges
between 52 to 58%) [4]. Despite being more sensitive than microscopic examination, it is time
consuming and expensive, therefore rarely used for clinical diagnosis [93].
4.1.1. Xenodiagnosis
A positive serological test result is not enough to prove that an infected dog is capable of
transmitting the pathogen to the vector. Lack of sensitivity contributes to the lack of diagnostic
control efficiency. The only technique that evaluates if an infected mammalian host can transmit
the parasite by natural means to the vector is xenodiagnosis [94–96]. Sandflies are placed inside
specific containers and placed in contact with dogs for a certain period of time for a blood meal
to occur. After the feeding, the sandflies are separated and the feeding rate is calculated. The
presence of parasites in the sandfly can be evaluated by direct observation of the promastigote
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forms by optical microscopy or Polymerase Chain Reaction (PCR). This test can be highly
specific and sensitive, depending on parasite load and procedure implementation [96].
4.1.2. Montenegro skin test
The Montenegro Skin Test evaluates the late cellular hypersensitivity response. A solution with
promastigotes is injected intradermally, and a positive result consists in the appearance of a
hardened papule, equal or greater than 5 mm after 48 hours of injection. The test is low cost
and highly sensitive (can reach over 90%). A positive result is possible within 3 months after
infection, and relates to the disease evolution. Specificity is low (around 75%) due to the
overall large number of false positive results in cases of unapparent infection and cross-
reactivity with some pathologies, as well as technical problems [97].
4.2. Molecular methodologies
PCR technology has become an indispensable tool for the diagnosis of many parasitic diseases,
including leishmaniasis. It suffers similar limitations to the parasitological tests, where the
success is limited by the quality of the sample (parasite rich specific locations), as these
techniques are based on the amplification of specific parasitic DNA sequences. Although
several DNA targets exist, like rRNA or ITS-1 gene, the most common DNA target is the
Leishmania kinetoplast (kDNA) present in the minicircles of the parasite [98]. The diagnostic
sensitivity of these approaches is above 95% [99, 100] . In asymptomatic dogs the reported
efficacy is lower, less than 70% [100]. Leishmania DNA has been found to be present in the
canine oral mucosa, and can possibly be used for diagnostic. Oral swabs have shown positive
results in molecular diagnosis of infected dogs. Although, in samples from asymptomatic
dogs, the diagnosis test showed lack of sensitivity. Oral swabs combined with conjunctival
ones can be used for detection of L. infantum in asymptomatic dogs. The big advantage of this
test is that the sample collection is non-invasive, and combining this two swab methods, can
significantly contribute for detecting different stages of the infection [101]. The sensitivity of a
PCR assay depends on three factors: the physicochemical conditions of the reaction, the
concentration of the DNA target and the selected PCR primers [38, 102, 103]. Amplification-
based methods include the conventional PCR and qPCR (quantitative polymerase chain reac-
tion) [104]. Real-time PCR (qPCR) is an innovative approach of target DNA quantification,
faster than conventional PCR [102].
Although these techniques have a higher sensitivity for asymptomatic cases and early-stage
infections when compared to serological methods, they imply high costs due to sophisticated
equipment, reagents and specialized personnel [103, 105, 106].
4.3. Serological diagnosis
Serological tests are based on the screening of antigen or antibodies. Antigen detection should
be more specific for diagnosis that antibody-based immunodiagnostic tests. Thus, antigen
levels are expected to correlate with parasite burden, being useful when antibody prediction
is deficient. This approach should avoid cross-reactivity and distinguish active from past
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infections [8]. However, this technique is still unreliable (lack of specificity and variable sensi-
tivity). Efforts are being made to improve this tool, as it stands as a promising approach.
Currently, most clinical and surveillance laboratories use serological techniques to detect
pathogen-specific antibodies, since direct methods are often either invasive, potentially fatal or
expensive. Leishmania infection is characterized by the presence of a significant humoral
response, leading to the production of antibodies against Leishmania species. Serological methods
to detect these anti-Leishmania antibodies are useful as alternative diagnosis tests for both human
and canine Leishmania infections [107]. The presence of anti-Leishmania antigens/antibodies in
both asymptomatic and symptomatic infected dogs has allowed the development of agglutina-
tion tests, immunofluorescent serologic tests (such as Western blotting), immunochroma-
tographic tests, and enzyme-linked immunosorbent assays (ELISAs). The sensitivity depends
on the methodology but the specificity will depend on the antigen used. Serological tests are the
current tests of choice to diagnose CanL. Although, these tests often lack sensitivity and specific-
ity due to dog low specific antibody titers in the early stages of infection. Significant cross-
reactivity has also been reported [108]. Additionally, after a successful treatment, antibody levels
take a while to decrease. This can mask a relapse, making it impossible to diagnose it. The
introduction of commercial vaccines against CanL raised concerns since it can lead to antibody
production andmight prevent accurate results in serological tests for the diagnosis. This may not
allow differentiating between Infected and Vaccinated Animals (DIVA) [19]. Most commercially
available vaccines against CanL are not DIVA. This difficults the serological identification of
animals that become sick or infected in the future [19].
4.3.1. Direct agglutination test
Originally created as an alternative to the risky procedure of splenic aspirates, the Direct Agglu-
tination Test (DAT) was the first antibody detection test used in VL diagnosis and has been used
for more than 25 years. DAT is a simple semi-quantitative diagnostic tool, with a high sensitivity
(91–100%), specificity (72–100%), accuracy, reliability and inexpensiveness [4, 109].
DATdetects parasite antibodies in infected blood or serum through direct agglutination. It is a
semi-quantitative method based on visual agglutinations obtained by the increased dilution of
blood or serum mixed with stained, killed parasites in V-shaped wells [110]. If the result is
negative (absence of anti-Leishmania antibodies) DAT antigen accumulates at the bottom of the
plate. If there are anti-Leishmania antibodies present, the antigens form a film over the well
(positive result) [6, 111]. DAT has some disadvantages; it requires moderate technical expertise
(the interpretation of the results depend on the person analyzing the results, creating inter-
observer discrepancy) [112], serial dilutions must be done (requiring a considerable volume of
antigen) and has a relatively long incubation time [112]. DAT results remain positive long after
the patient is cured (anti-Leishmania antibodies can persist for years as a result of a VL
infection), making this test inappropriate for detecting relapses [8].
4.3.2. Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) is an important serodiagnosis technique used in
almost all infectious diseases, including VL. ELISA assays are based on the detection of
Biomarkers in Leishmaniasis: From Basic Research to Clinical Application
http://dx.doi.org/10.5772/intechopen.75315
209
antibodies present in blood or serum. An antigen/recombinant protein is used to coat the plate
and samples are added and incubated. A secondary antibody conjugated with an enzyme
recognizes and binds to the primary antibody. After adding a substrate, product susceptible
to colorimetric determination is developed and the results can be measured by optical density
techniques.
This tool is frequently used to detect anti-Leishmania antibodies due to its high sensitive and
specificity as well as good reproducibility and high throughput screening of large number of
samples, at an affordable expense. However, the specificity of this technique depends on the
antigen used. ELISA’s major disadvantage is its inadaptability in poor-resource field condi-
tions and requiring specialized operators.
4.3.3. Indirect fluorescent antibody technique
Indirect Fluorescent Antibody Technique (IFAT) is an extremely valuable tool that allows
assessment of anti-Leishmania antibody titers produced by infected individuals. It is a quite
useful method in epidemiological studies and in clinical practice [113]. Promastigote or
amastigote forms have been used as a source for antigens used by IFAT [25]. IFAT is based on
the use of fluorophores to detect antibodies that recognize the parasites. It involves the use of a
primary antibody that binds to the antigen and allows the formation of an antigen-antibody
complex. Posteriorly, the binding of a fluorophore-conjugated secondary antibody results in an
amplified signal that can be examined by fluorescence microscopy. IFAT is the serological gold
standard for diagnosis of CanL in most countries. This analytical methodology differs from
ELISA as it resorts to the whole body parasite as antigen [113]. Although having a high
specificity and sensitivity (100% and 90%, respectively), IFAT sensitivity is lower for asymp-
tomatic infections when compared to ELISA [29, 114].
4.3.4. Immunochromatographic tests
Immunochromatographic (IC) tests are recurrently used in large-scale screenings. The results
obtained from IC tests consider the epidemiological context and do not require antibody
titration [115]. IC test is based on chromatographic and relies on capillary action. An antigen-
antibody complex is formed and entrapped on the membrane. The sample migrates across this
membrane, the antibodies present in the blood recognize the antigen and the labeled antibody
present in the membrane resulting in the formation of a colored product. IC tests are inexpen-
sive, practical, rapid and suitable for field use. However, these tests frequently lead to false
positives with patients in endemic regions that have already been infected in the past. Resul-
tantly, this technique does not work in the diagnosis of relapsed patients [115]. Much like
ELISA, the specificity and sensitivity of IC test is dependent on the antigen used.
4.3.5. Flow cytometry
Flow Cytometry (FC) is an emerging technique for the diagnostic of several infectious diseases
[116]. It has a high throughput capacity, possibility of quantification, high reproducibility and
sensitivity and potential for multiplexing [49]. This technique analyses and sorts cells or
particle suspensions in a controlled fluid stream, through the measurement of fluorescence
and scatter induced illumination, allowing the acquisition of structural and functional data.
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The flow cytometry technique can quantify the antibodies against Leishmania surface antigens,
restraining potential cross-reactivity against more conserved intracellular structures [117] and
showing potential to monitor post chemotherapy VL, in order to evaluate the success of
treatment [118].
As described before, every diagnosis technique has its downsides. Parasite demonstration in
tissue smears and culture provide definitive diagnosis of VL, but generally have a lower
sensitivity than serologic methods with a high risk associated. Microscopy techniques lacks
sensitivity, whereas culture requires a longer time to obtain a result and is vulnerable to
contamination [119].
Molecular diagnostic tools like PCR and real-time PCR are quite sensitive and specific although
difficult to perform in field conditions and costly [8]. Its use remains largely restricted to some
hospitals and research centers [90].
Serological tests are often not sensitive enough to detect asymptomatic individuals, having to
be combined with classical methods of diagnosis to confirm. ELISA, IFAT, DAT and rK39
immunochromatographic strip test (ICT) are highly sensitive and specific when analyzing
active VL in immunocompetent individuals. This does not happen when titers decline and
parasite charge is lower. Due to this, false negative results frequently happen in immunocom-
promised patients and asymptomatic Leishmania infections [120].
In that way, the big challenge in the field is to isolate, recombine, produce and identify new
proteins capable of detecting asymptomatic leishmaniasis cases and early stages of infection
in VL endemic regions, using safe techniques that are easy, fast, sensitive and with a fair
cost.
The importance of serological methods has been rising in vector-borne diseases, due to the low
sensitivity associated to the microscopic methods [52]. Molecular biology developments over
the years have led to advances in techniques that aided in VL control and had significant
progress in surveillance and diagnosis of this disease [52].
The main problem with leishmaniasis diagnosis is the identification of markers that can detect
the presence of low titres of antibodies. Thus, new markers are needed to contribute for a more
accurate diagnosis capable of detecting asymptomatic cases and early stages of disease in large
screening studies [38, 121].
5. Successful diagnosis approaches-from laboratory to field conditions
Currently, the scientific community is investing in developing VL tests based on antigen detec-
tion, such as rapid diagnostic tests.
Rapid diagnostic tests (RDTs) are equipment-free diagnostic devices that are adequate for field
conditions. The results of this test can be read easily and in a short amount of time. Most RDTs
work by capturing either an antigen or an antibody on a solid surface and then attaching
molecules that allow detection by the naked eye.




These Immunochromatographic Tests (ICTs) usually based on immunochromatography with a
dipstick, are used for VL diagnosis using protein from Leishmania as the antigen [110]. The
RDTs for VL, above all but not exclusively the rK39-based ICTs, seem to be the present solution
for field diagnosis in field settings due to their ease of use, convenience and cost, making them
potentially favorable to increase patients’ access to VL diagnosis and treatment [110]. There is a
limited number of commercially available RDTs for VL [110] (Table 2).
The scientific technological advances in recombinant antigens as reagents for the serological
diagnosis of VL have resulted in high sensitivity and specificity of the serological tests. Several
recombinantproteinshavebeen shown tobeuseful for thediagnosis ofLeishmania infectionboth in
humans and dogs [34]. Recombinant antigens such as the abovementioned rK9, rK16, rK26, rK28
and rk39 have been evaluated for its potential use in rapid diagnostic tests in field conditions.
Of all commercial RDTs, the rK39 is the most widely used. The rK39 rapid immune-
chromatographic dipstick test was developed to meet the need for diagnosis in field condi-
tions. Among the recombinant antigens, this one showed promising diagnosis and has been
extensively tested in the last 5 years with IC tests in several leishmaniasis endemic areas [60,
122], being associated with several commercial applications (Table 2). It is an easy and quali-
tative test able to detect anti-Leishmania circulating antibodies, not requiring scientifically
trained personnel. The test procedure involves adding the patient’s blood or serum with
diluent buffer on the strip [110]. These rK39 ICTs give an immediate result (typically between
10 and 20 minutes) and give a binary reading (positive or negative) [110]. This test has been
approved by the Food and Drug Administration and tested by the World Health Organization
in many endemic countries. The rapid rK39 immunochromatographic dipstick test is both
Application Product name Bound antigen Manufacturer
Human DiaMed-IT LEISH rK39 Bio-Rad Laboratories
OnSite Leishmania Ab Rapid Test rK39 CTK Biotech, Inc
Crystal KA (Kala azar) rKE16 Span Diagnostics, Lda
Kalazar Detect™ rK39 InBios International Inc
Dog Canine Visceral Leishmaniasis Dipstick* rK39 InBios International Inc
Anigen Rapid Leishmania Ab Test Kit Na Vtrade
Anigen Rapid Leishmania Ab Test Kit Na BIONOTE
Speed Leish K Kinesin Capture Complex Virbac Animal Health
DPP® Canine Leishmaniasis rK39 Bio-Manguinhos/Fiocruz
ImmunoRun Na Biogal, Galed Labs.
Canine Leishmania Antibody Test HRPO Conjugate Quicking Biotech
Leishmania Ab na EcoDiagnóstica
Data representative of available information in 2016.
Table 2. Immunochromatographic tests available for Leishmania diagnosis.
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sensitive (67–100%) and specific (70–100%) [34]. In the Indian subcontinent (India and Nepal),
the test proved to have a high sensitivity and specificity but in East Africa (Sudan, Kenya and
Ethiopia) the results were not so remarkable [34, 123]. These results in East Africa are not
entirely understood; however, lower antibody levels for rK39 in this region might be the
reason for these decreased values of sensitivity and specificity [31]. Several studies have been
carried out using the dipstick form of rK39 in dogs. The results revealed an overall good
sensitivity in symptomatic dogs, although the number of studies for a proper analysis is too
small for a detailed comparison [34, 124]. This recombinant antigen can also be used in a latex
agglutination test, where latex is used for antigen absorption. The attachment of molecules to
latex particles can be accomplished through either physical adsorption or covalent coupling.
However, the sensitivity of this latex test is relatively low [34]. In comparison to DAT and
ELISA, dipstick rK39 is a better choice for field conditions, sufficiently sensitive and highly
specific method for the diagnosis of active VL in humans as well as in dogs [34].
The diagnosis of CanL remains a problem due to lack of sensitivity or specificity in the current
diagnostic tests. Nevertheless, rapid tests like the immunochromatographic-dipstick test using
rK39 and rK26 proteins of L. infantum [32] as antigens seem to be most appropriate for
diagnosis of symptomatic cases of CanL but lack sensitivity for asymptomatic dogs. Research
should continue in order to develop a more sensitive and specific recombinant assay able to
detect asymptomatic cases [31].
5.2. Latex agglutination kit
Latex Agglutination Kit (KATex) is a simple, noninvasive, rapid, reliable and easily executable
extensively used in diagnosis of L. donovani in endemic areas as Sudan, India and Nepal. It is
not commonly used in L. infantum endemic areas [125]. Latex beads coated with anti-Leish-
mania antibodies detect the presence of a low molecular weight, heat-stable glycoconjugate
antigen in urine [126]. This antigen is present in both promastigote and amastigote forms of VL
patients with active infection. It has a high specificity (from 82 to 100%) and a sensitivity that
varies from 47 to 95%. Although, for immunocompromised patients, the sensitivity and spec-
ificity have been reported at 85–100% and at 96–100%, respectively. The antigen may be
detectable from one to 6 months after treatment. The method is appropriate for the diagnosis
of primary VL, for monitoring the efficacy of treatment and for the detection of sub-clinical
infection. KAtex test was also tested with oral fluids, which demonstrated the usefulness of
oral-fluid collection in the detection of both Leishmania antibodies and DNA [125]. Sensitivity
was higher in saliva that in urine, but specificity was lower. The immunoassay probably
detects the same antigen present in urine [125].
6. Conclusion and remarks
Currently, several biomarkers for diagnosis are available in research laboratories, with expen-
sive and sophisticated equipment requiring trained operators, precluding their direct applica-
tion for field use.
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Due to the specific characteristics associated to serological methodologies, they are accepted as
the ideal diagnosis approach for both human and animal use, enabling epidemiological stud-
ies. Still, a significant limitation of serological tests is their capacity to detect asymptomatic
cases. Further challenges associated to the advent of vaccination still need to be addressed.
Ultimately, the goal is to find biomarkers that detect different clinical forms of the disease that
can be used universally in a rapid diagnosis kit.
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